Research programme: triplex forming oligonucleotide-tomaymycin conjugate - Nanogen

Drug Profile

Research programme: triplex forming oligonucleotide-tomaymycin conjugate - Nanogen

Alternative Names: TFO-PBD conjugate; TFO-tomaymycin conjugate

Latest Information Update: 19 Aug 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nanogen
  • Class Drug conjugates; Oligonucleotides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Suspended Cancer

Most Recent Events

  • 09 Jul 2009 Nanogen completes sale of substantially all of its assets and its subsidiaries, Epoch BioSciences and Nanotronics, to Financiere Elitech and DxCon
  • 29 Dec 2004 Epoch Biosciences has been acquired and merged into Nanogen
  • 24 Jul 2003 Preclinical development for Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top